Circulating Endothelial Cells as a Biomarker in Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcome

Najjar, Fadi; Alammar, Moosheer; Bachour, Marroan; Al-Massarani, Ghassan

doi:10.5301/jbm.5000100

Cited by 10 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current prospective study, we investigated the role of CECs and their kinetic modifications after first-line platinum-based chemotherapy for predicting tumor response and survival in advanced NSCLC. As previously reported (23, 32, 33), we found that CEC levels in NSCLC patients at baseline and after chemotherapy were much higher than in healthy subjects. This is probably due to the angiogenic switch associated with cancer growth and the related production of angiogenic growth factors and possibly others by cancer cells and/or various host cells (17).…”

Section: Discussionsupporting

confidence: 88%

“…Similar results were recorded for both PFS and OS in advanced nonsquamous subtypes according to the mean level of CECs quantified using the semiautomated IMS technique (36). However, no significant difference in baseline CEC levels was observed among histological subtypes in NSCLC (33, 37). The lack of a correlation between baseline CEC levels and PFS or OS may be due to the relationship between survival rates and the response to second-line chemotherapy in advanced NSCLC patients.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy

Najjar

Al-Massarani

et al. 2015

Int J Biol Markers

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 78%

Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy

Najjar

Al-Massarani

et al. 2015

Int J Biol Markers

Self Cite

View full text Add to dashboard Cite

show abstract

“…We hypothesized that poorly differentiated tumor cells exhibit strong invasiveness, and are therefore more likely to be transferred to the blood and distant organs. Our results are consistent with the available related literature (19,20).…”

Section: Discussionsupporting

confidence: 83%

Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy

Liu¹,

Ling²,

Qi³

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The identification of circulating tumor cells (CTCs) may provide important prognostic information in several types of solid tumors, including gastric cancer. The aim of this study was to investigate whether CTC count may be used to predict survival in patients with advanced gastric cancer treated with chemotherapy. The CELLection™ Epithelial Enrich kit was used to isolate and purify CTCs from samples of peripheral blood. Immunofluorescent staining was used for CTC counting. High CTC counts were associated with poor tumor differentiation and high serum CEA levels (P=0.021 and 0.005, respectively). After 3 months, 16 patients with decreasing CTC counts after the first cycle of chemotherapy obtained complete response, partial response or stable disease, while 13 patients with increasing CTC counts developed progressive disease. The patients with decreasing CTC counts also exhibited longer progression-free survival (PFS) (P≤0.001) and overall survival (OS) (P= 0.002) compared with those with increasing CTC counts. Among all 59 patients, those with a CTC count of ≤2 cells̸5 ml blood exhibited longer PFS (P≤0.001) and OS (P≤0.001) compared with those with a CTC count of >2 cells̸5 ml blood. The multivariate analysis suggested that an increase of the CTC count after the first cycle of chemotherapy was only an independent prognostic marker of poor PFS (P=0.019). However, a baseline CTC count of >2 cells̸5 ml blood was an independent poor prognostic marker for PFS (P= 0.008) and OS (P= 0.001) in all 59 patients. Our study suggested that patients with a low baseline CTC count or decrease of the CTC count after the first cycle of chemotherapy may benefit significantly from palliative chemotherapy. In conclusion, CTC count may be a good chemotherapy monitoring marker and an ideal prognostic marker for patients receiving palliative chemotherapy.

show abstract

“…These cells are heterogeneous in size (15–50 µm), carry the markers of ECs (e.g., VWF, CD144 and CD146), but not leukocyte markers (CD45), and serve as noninvasive markers of EC damage and dysfunction. Al-Massarani and colleagues demonstrated a reduction in circulating ECs after acute- and fractionated-dose gamma irradiation in rat peripheral blood, with an incomplete recovery 2 months postirradiaton (91), and in patients undergoing chemotherapy (92, 93). The presence of systemic signalers of processes, such as the oxidative stress pathway and inflammation, is attractive since there is vast potential for a noninvasive or minimally invasive source of biomarkers for early and delayed progression of injury.…”

Section: Introductionmentioning

confidence: 99%

Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015

2016

View full text Add to dashboard Cite

After the events of September 11, 2001, a decade of research on the development of medical countermeasures (MCMs) to treat victims of a radiological incident has yielded two FDA-approved agents to mitigate acute radiation syndrome. These licensed agents specifically target the mitigation of radiation-induced neutropenia and infection potential, while the ramifications of the exposure event in a public health emergency incident could include the entire body, causing additional acute and/or delayed organ/tissue injuries. Anecdotal data as well as recent findings from both radiation accident survivors and animal experiments implicate radiation-induced injury or dysfunction of the vascular endothelium leading to tissue and organ injuries. There are significant gaps in our understanding of the disease processes and progression, as well as the optimum approaches to develop medical countermeasures to mitigate radiation vascular injury. To address this issue, the Radiation and Nuclear Countermeasures Program of the National Institute of Allergy and Infectious Diseases (NIAID) organized a one-day workshop to examine the current state of the science in radiation-induced vascular injuries and organ dysfunction, the natural history of the pathophysiology and the product development maturity of potential medical countermeasures to treat these injuries. Meeting presentations were followed by a NIAID-led open discussion among academic investigators, industry researchers and government agency representatives. This article provides a summary of these presentations and subsequent discussion from the workshop.

show abstract

Circulating Endothelial Cells as a Biomarker in Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcome

Abstract: Increased CEC counts were present in patients with newly diagnosed NSCLC compared with healthy subjects. Elevated levels of baseline CECs correlated with high-risk factors in NSCLC. In addition, increased CEC count during follow-up seems to be correlated with recurrence in NSCLC patients.

Cited by 10 publications

References 36 publications

Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy

Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy

Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy

Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015

Contact Info

Product

Resources

About